Company news

Revive Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases

September 15, 2026

Revive Therapeutics Announces Proposed Shares for Debt Settlement

August 19, 2026

Revive Therapeutics Reports Grant of Options

August 14, 2026

Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

August 12, 2026

Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

July 15, 2026

Revive Therapeutics Announces Proposed Private Placement

June 26, 2026

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

May 20, 2026

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

December 15, 2025

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

September 19, 2025

Revive Therapeutics Announces Extension of Proposed Private Placement

September 5, 2025

Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

August 11, 2025

Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

July 30, 2025

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

July 8, 2025

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

June 26, 2025

Revive Therapeutics Advances with Next-Generation Bucillamine Development

June 4, 2025

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

May 12, 2025

Revive Therapeutics Announces Proposed Shares for Debt Transaction

April 21, 2025

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

April 10, 2025

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

April 1, 2025

Revive Therapeutics Announces Results of Annual Shareholder Meeting

March 19, 2025

Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

March 3, 2025

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

February 3, 2025

Revive Therapeutics Prices and Files Final Prospectus for Equity Financing

December 5, 2014

Decks

The 5 newest of 32 decks. Every deck is listed under its year.